JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Publication history |
Reprints |
Permissions |
Cite this article as |
Share |
YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
SPECIAL ARTICLE Free access
Minerva Medica 2020 August;111(4):362-4
DOI: 10.23736/S0026-4806.20.06616-1
Copyright © 2020 EDIZIONI MINERVA MEDICA
language: English
Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19?
Daniele SAVERINO 1, 2 ✉
1 Department of Experimental Medicine, University of Genoa, Genoa, Italy; 2 San Martino Hospital, Genoa, Italy
Currently, there are no approved specific antiviral agents for novel coronavirus disease (COVID-19). Hyper-immune/convalescent plasma derived from recently recovered donors seems to be useful to treat COVID-19 patients, an addition to maximal supportive care and antiviral agents. The endpoints are the improvement of clinical symptoms and laboratory parameters of these patients. However, the efficacy of hyper-immune/convalescent plasma treatment for severe infectious diseases is still controversial. The optimal dose and time point, as well as the clinical benefit of hyper-immune/convalescent plasma therapy, needs further investigation in larger well-controlled trials.
KEY WORDS: COVID-19 serotherapy; COVID-19; Therapeutics